Company New Pharma Srl with Fiscal Code 23688007
recorded a turnover of 2024 of
796.389,
with a net profit of
88.017
and having an average number of employees of
6.
The company operates in the field of Comerţ cu amănuntul al produselor farmaceutice having the NACE code 4773.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
New Pharma Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
434.807
445.232
500.183
541.283
574.339
614.906
648.706
640.339
705.496
796.389
Total Income - EUR
451.737
462.205
525.251
552.982
574.362
614.938
648.739
640.355
705.508
796.698
Total Expenses - EUR
391.072
394.487
435.488
441.474
457.349
510.119
548.862
547.849
607.741
691.915
Gross Profit/Loss - EUR
60.665
67.718
89.763
111.509
117.013
104.819
99.877
92.507
97.768
104.783
Net Profit/Loss - EUR
50.959
56.883
83.895
105.979
111.270
98.670
93.389
86.103
82.125
88.017
Employees
7
6
6
5
0
6
6
6
6
6
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 13.5%, from 705.496 euro in the year 2023, to 796.389 euro in 2024.
The Net Profit increased by 6.352 euro, from 82.125 euro in 2023, to 88.017 in the last year.
Check the financial reports for the company - New Pharma Srl
Financial Rating - NEW PHARMA SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - New Pharma Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - New Pharma Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - New Pharma Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
New Pharma Srl - CUI 23688007
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Fixed Assets
9.720
9.259
23.120
19.375
15.767
12.749
8.948
5.894
1.846
22.755
Current Assets
189.993
139.386
162.892
181.476
218.159
234.677
222.975
189.378
211.413
232.018
Inventories
99.258
82.899
101.458
97.397
141.382
159.492
147.768
123.889
141.283
155.808
Receivables
43.523
21.199
58.630
57.451
44.881
58.844
63.285
58.639
60.547
59.691
Cash
47.211
35.288
2.805
26.627
31.897
16.340
11.922
6.851
9.582
16.519
Shareholders Funds
92.596
56.586
83.603
188.048
219.813
231.621
218.799
179.859
194.724
242.834
Social Capital
45
45
44
43
42
41
40
41
40
40
Debts
107.116
92.059
102.409
12.803
14.114
15.805
13.124
15.414
18.534
11.939
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9743
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
Main CAEN
"4773 - 4773"
CAEN Financial Year
4773
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
232.018 euro in 2024 which includes Inventories of
155.808 euro, Receivables of
59.691 euro and cash availability of
16.519 euro.
The company's Equity was valued at
242.834 euro, while total Liabilities amounted to
11.939 euro.
Equity increased by 49.198 euro, from 194.724 euro in 2023, to 242.834 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - New Pharma Srl